News

BIO-CAT Announces Safety Study on New Enzyme Addressing High FODMAP Foods

BIO-CAT, an industry-leading enzyme supplier headquartered in Virginia, is excited to announce the publication of a groundbreaking safety clinical trial manuscript featuring its proprietary ingredient, OPTIZIOME® Inulinase  (now marketed as OPTIZIOME® Fructanase), in Gastro Hep Advances.

Fructanase, also known as inulinase, was developed to address the unintended consequences of digestive discomfort from certain foods, more specifically foods high in FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols), including certain vegetables, grains, and fruits. Notably, many vegetables and fruits contain a specific FODMAP called fructans which cause digestive discomfort1. Fructanase is an enzyme which breaks down fructans, offering potential solutions for digestive health.

BIO-CAT’s OPTIZIOME® Fructanase has reached new heights within the dietary supplement industry as one of only 6 other fungal and microbial enzymes within the past decade to be granted a New Dietary Ingredient Notification (NDIN) from the FDA. BIO-CAT’s rigorous safety dossier on OPTIZIOME® Fructanase was reviewed by GRAS associates, a division of SGS Nutrasource (Guelph, Ontario, Canada), ensuring compliance with FDA standards. According to the FDA, an NDIN must provide evidence supporting the safety of a new dietary ingredient under recommended conditions of use.

The efficacy of OPTIZIOME® Fructanase was demonstrated in a Phase I clinical trial, which showcased its safety profile and potential in reducing gastrointestinal symptoms associated with FODMAP consumption. The trial was conducted as a randomized, double-blind, placebo-controlled study with 60 healthy participants aged 20–65 years.

The study, managed by Nutrasource, yielded promising results. It concluded that high-dose fructanase supplementation was safe and well tolerated, with no significant differences in GI outcomes compared to placebo over a 4-week period. Moreover, participants in the fructanase group experienced fewer adverse events, with no notable changes in clinical parameters.

Chris Schuler, CEO of BIO-CAT, emphasizes the company’s dedication to addressing these challenges: “All market indicators point towards consumers seeking healthier meal options, including high FODMAP dietary choices. As a company focused on digestive health, we understand the challenges consumers could face. I’m excited that the team was able to bring a new enzyme application to our customers and partners that addresses the growth of high FODMAP foods.”

Lois Lin, Medical Writer and Team Lead at SGS Nutrasource, says “We are delighted to congratulate BIO-CAT on the successful completion and publication of their clinical trial for microbial fructanase, a novel enzyme to aid the digestion of hard-to-digest fibers. This milestone is a testament to the collaborative efforts of the dedicated research teams, investigators, and study participants. At SGS Nutrasource, we are proud to have played a vital role in the design and conduct of this clinical trial, and look forward to BIO-CAT’s continued progress in bringing this novel enzyme to the market.”

BIO-CAT remains committed to advancing digestive health solutions through innovative enzyme technologies, with OPTIZIOME® Fructanase poised to make a significant impact on consumer well-being.

 

Learn more here.

Recent News

06/02/2025

Virginia Tech researchers find promise in a new peptide drug to combat a deadly brain cancer

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer. In a study published May 16 in Cell Death and Disease, researchers identified a previously unknown trait of cancer cells that

05/28/2025

Brandy Salmon named Virginia Tech’s first vice president for innovation and partnerships

Brandy Salmon, who since 2017 has led Virginia Tech teams focused on connecting the university with corporations, foundations, and alumni worldwide has been named the university’s first vice president for innovation and partnerships. “True collaboration between higher education, government, and industry is essential for success in today’s evolving landscape,” said Virginia Tech President Tim Sands.

05/28/2025

Avera Joins Civica to Help Minimize Risk of Drug Shortages

Civica, a nonprofit pharmaceutical company created to prevent and mitigate drug shortages, announced today that Avera, a leading nonprofit healthcare provider in the Upper Midwest United States, has joined the company in helping protect patients from the impact of drug shortages of essential generic sterile injectable medicines. Drug shortages are a persistent challenge to the